Rohto Pharmaceutical Accelerates Social Implementation of 'Longevity' Science Based on Cell Research
Key facts
- Rohto Pharmaceutical Accelerates Social Implementation of 'Longevity' Science Based on Cell Research
- Rohto Pharmaceutical Co., Ltd. announced it will accelerate the social implementation of 'Longevity' science based on its long-standing cell science research. As the first phase, the company will sequentially deploy 'Phyto-exosome' technology, derived from plants, microorganisms, and algae, into its core skincare brands: 'Hada Labo', 'Melano CC', and 'Obagi'.
- Source: PR Times
- Date: May 29, 2026
Direct answer
Rohto Pharmaceutical Co., Ltd. announced it will accelerate the social implementation of 'Longevity' science based on its long-standing cell science research. As the first phase, the company will sequentially deploy 'Phyto-exosome' technology, derived from plants, microorganisms, and algae, into its core skincare brands: 'Hada Labo', 'Melano CC', and 'Obagi'.
- Citation
- Rohto Pharmaceutical Accelerates Social Implementation of 'Longevity' Science Based on Cell Research (May 29, 2026), PR Times
- Source
- PR Times
- Date
- May 29, 2026
Rohto Pharmaceutical Co., Ltd. announced it will accelerate the social implementation of 'Longevity' science based on its long-standing cell science research. As the first phase, the company will sequentially deploy 'Phyto-exosome' technology, derived from plants, microorganisms, and algae, into its core skincare brands: 'Hada Labo', 'Melano CC', and 'Obagi'.
📋 Article Processing Timeline
- 📰 Published: May 29, 2026 at 20:00
- 🔍 Collected: May 30, 2026 at 23:22 (27h 22m after Published)
- 🤖 AI Analyzed: May 30, 2026 at 23:24 (1 min after Collected)
As the first phase, the company will sequentially deploy 'Phyto-exosome' technology, derived from plants, microorganisms, and algae, into its core skincare brands: 'Hada Labo', 'Melano CC', and 'Obagi'. By implementing this as a foundational technology spanning its brand groups rather than just individual products, the company aims to deliver advanced 'Longevity' science as a relatable value to more customers.
In recent years, as domains such as health, medicine, beauty, food, and technology converge and the extension of healthy life expectancy becomes a key social theme, the company is integrating its accumulated business and R&D into the 'Longevity' domain for social implementation.
■ Rohto Pharmaceutical's Longevity rooted in 'Cell Research'
For Rohto Pharmaceutical, 'Longevity' does not simply mean extending lifespan, but enabling people to live long, healthy, and youthful lives. Supporting this state requires homeostasis—the ability of bodies, organs, and cells to remain in harmony. Rohto's longevity research starts with 'cell research' to scientifically understand the mechanisms of homeostasis maintenance and reveal how to preserve a healthy, youthful state.
In the era of the 100-year life, living healthily is not only an individual wish but also a challenge linked to the vitality of families, communities, and society. Having accumulated expertise over many years through cell research in areas ranging from gastrointestinal drugs, eye drops, and skincare to oral supplements, food, medicine, and regenerative medicine, the company has been able to decipher the mechanisms supporting a healthy, youthful state through science. The company considers it its mission to implement the knowledge gained through such research into society in forms that reach consumers, such as products and services.
■ Phyto-exosome technology deployed in core skincare brands
In addition to the cell science cultivated in the medical field, Rohto has long explored the power of plants, microorganisms, and algae, including extracts and herbal medicines. To further develop this knowledge and scientifically elucidate the potential of the life information contained in plants and algae, the company established the 'Phyto Science Research Institute' in 2025. As its core technology, it is advancing research on 'Phyto-exosomes', focusing on extracellular vesicles derived from plants, microorganisms, and algae.
Phyto-exosomes represent a new research domain that connects Rohto's accumulated cell science with the diverse potential of plants, microorganisms, and algae. The company positions this as a vital technology to transform 'Longevity' science into value that reaches consumers.
As the first step, this technology will be deployed in the 'Hada Labo', 'Melano CC', and 'Obagi' brands. To make advanced 'Longevity' science accessible in daily life, it will be rolled out widely, from high-end and clinic-channel brands to mass-market brands.
■ Towards the medium-to-long term
This new direction of becoming a 'company that promotes and realizes Longevity' is not about launching a standalone new business; it is a policy to enhance existing business value and strengthen the foundation for medium-to-long-term growth by leveraging the cell research and business foundations built since the company's founding. Looking ahead, Rohto aims to gradually expand value provision centered on Longevity from skincare to medicine, oral supplements, and food.
Under the slogan 'Connect for Well-being & Longevity', Rohto will deploy its Japan-originated 'Longevity' science, based on cell research, to society and the world, contributing long-term to people's healthy lives.
FAQ
What technology is Rohto Pharmaceutical deploying in Hada Labo products as part of its longevity science initiative?
Rohto Pharmaceutical is deploying 'Phyto-exosome' technology in Hada Labo products based on plant and algae research.
Which specific Rohto Pharmaceutical brands will receive Phyto-exosome technology by 2024?
Hada Labo, Melano CC, and Obagi are the specific Rohto brands to receive Phyto-exosome technology.
How does Rohto Pharmaceutical's Phyto-exosome technology relate to cell research in 2024?
Phyto-exosome technology is based on Rohto's long-standing cell science research focused on plant and microbial cells.
What is the primary scientific basis for Rohto's longevity initiative launched in 2024?
The primary basis is Rohto's long-standing cell science research, now applied through Phyto-exosome technology.
When did Rohto Pharmaceutical announce the deployment of Phyto-exosome technology in Obagi products?
Rohto Pharmaceutical announced the deployment of Phyto-exosome technology in Obagi in 2024.